Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07832227) titled 'Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Dana-Farber Cancer Institute
Condition:
Low Grade Ovarian Serous Adenocarcinoma
Endometrial Cancer
Intervention:
Drug: Imlunestrant
Drug: Abemaciclib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 1, 2026
Target Sample Size: 60
To know more, visit https://clinicaltrials.gov/study/NCT07832227
Disclaimer: Curat...